Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic, triple negative, PD-L1 positive breast cancer that has not been previously treated.
Status In progress
Process STA 2018
ID number 2705

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
29 May 2020 - 29 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 January 2020 In progress. Referred September 23 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance